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Background
Breast cancer is the first cause of oncologic female death
in western countries [1]. Current medicine is continu-
ously looking for a treatment that is the least invasive
and the maximum conservative as possible.
Magnetic Resonance guided Focused Ultrasound
(MRgFUS) is a non-invasive ablation technique that relies
on the use of a high-intensity focused ultrasound beam
that can increase the punctual temperature within a target
tissue, causing a consequent thermal damage and coagula-
tion necrosis [2,3]. The Magnetic Resonance guidance
allows a better visualization of the lump and the real time
temperature monitoring during the entire treatment [4].
Materials and Method
The aim of this multicentric, prospective study is to
assess safety and feasibility of MRgFUS ablation of inva-
sive ductal breast cancer (IDC) (stage T1 N0 M0).
Main inclusion criteria are: women > 18 years-old with
biopsy-proven invasive ductal carcinoma (T1 N0 M0); the
presence of a single lump with 2 cm maximum diameter
visible at contrast-enhanced MRI; a minimum distance of
10 mm between the lump and the skin layer, the pectoral
muscle and the nipple.
All procedures were performed on 3T MR scanner
(GE Medical Systems), featuring a HIFU transducer
embedded into the patient table (ExAblate 2100,
InSightec, Haifa - Israel). Treatment was performed
under conscious sedation with patients placed in prone
position. Baseline and gadolinium-enhanced sequences
were acquired in order to define the ablation area and
confirm the correct patient positioning.
Ablation volume included the enhancing tumor + 5 mm
margin. Skin layer and rib cage were defined in order to
be protected from high energy levels. The system automa-
tically generated a treatment plan taking into account the
anticipated energy delivered through the skin to the region
of treatment. After verifying the correct target area using
low-power sub-therapeutic sonications, treatment started
at full therapeutic power. At the end of each treatment,
the same sequences performed before the procedure were
acquired to confirm the ablation area and the absence of
thermal damage to adjacent tissues. Patients were exam-
ined for any adverse events and monitored for 3-4 hours
prior to discharge. Within 14 days after the procedure all
the patients underwent surgical lumpectomy for the histo-
pathology analysis.
Results
Five patients have been treated in the study. In 3/5 patients
histopathology confirm 100% necrosis of the tumor sur-
rounded by fibrosis (Fig. 1). In the remaining 2 patients his-
topathology found respectively 15% and 70% of residual
tumor; in this latter case in particular, an irreversible
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reflection of the ultrasound beam caused by possible air
bubbles between the transducer and the skin.
No treatment-related adverse events were recorded
after the treatment or during the follow-up period prior
to lumpectomy (10-15 days).
Conclusion
Even if the study is still in progress, our preliminary
results show that MRgFUS is a safe and effective non-
invasive ablation modality in patients with localized
breast invasive ductal cancer.
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Figure 1 47-years old female with left breast IDC. Contrast enhanced fat suppressed 3D T1-weighted GRE sequence acquired in axial plane (a)
shows a 10 mm lump located between upper quadrants (arrows). After MRgFUS treatment the same sequence (b) shows the complete absence
of enhancing tissue surrounded by some hyperemia due to gland inflammation. Microscopy (c) confirmed the necrosis area surrounded by
fibrotic tissue.
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